November 14, 2011 - Timothy Gardner (past-president of the American Heart Association) and Frank Sellke (Chairman of the Council on Cardiovascular Surgery and Anesthesia of the American Heart Association) review Cytograft’s first in human clinical results HERE.
July 15, 2011 - Cytograft highlighted in cover story in Medical Device Daily, found HERE.
June 27, 2011 - Dr. McAllister presents Cytograft's allogeneic vascular graft at the American Heart Association's prestigious Emerging Science series. The presentation can be found HERE.
June 20, 2011 - Cytograft publishes an article in Endovascular Today
December 8, 2010 - Dr. Nicolas L'Heureux, Cytograft's Chief Scientific Officer, opens and chairs the session Tissue Engineering and Regenerative Medicine in the Clinic at the North American meeting of TERMIS in Orlando, Florida.
November 22, 2010 - Dr. L'Heureux, co-founder and CSO of Cytograft, is featured in the "Industry Spotlight" of the Biomedical Engineering Society.
TEAM
Todd McAllister portrait

Dr. Todd McAllister, Ph.D. - Co-Founder and CEO of Cytograft Tissue Engineering

Dr. McAllister received his Ph.D. in BioMedical Engineering from the University of California, San Diego. He is the co-founder and CEO of Cytograft Tissue Engineering, Inc. Dr. McAllister has been an early proponent of biological approaches to tissue engineering that do not require synthetic scaffolds. Dr. McAllister has also pioneered a novel business strategy within Regenerative Medicine, taking Cytograft’s lead product, the Lifeline™ Vascular Graft from inception to commercial licensure in Europe on less than $10M in private equity.

Dr. McAllister’s is also the Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, where he oversees a broader range of cell-based cardiovascular repair technologies. He also serves on several advisory boards, including Lumen, Biocardia, and the Medical University of South Carolina. Nicolas L'Heureux Portrait

Dr. Nicolas L'Heureux, Ph.D. - Co-Founder and CSO of Cytograft Tissue Engineering

Dr. L’Heureux received his Ph.D. in Cell Biology from Laval University in Quebec, Canada and was a post-doctoral AHA fellow in the Department of Bioengineering at the University of California, San Diego. He is the co-founder and CSO of Cytograft Tissue Engineering, Inc. Dr. L'Heureux invented Tissue Engineering by Self-Assembly (TESA), a novel tissue engineering strategy. He advocates a biological approach to Regenerative Medicine, minimizing the inclusion of synthetic scaffolds and exogenous biomaterials.

Dr. L'Heureux is also the Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta. As a co-director he oversees research of cell-based cardiovascular repair technologies. Nathalie Dusserre portrait

Dr. Nathalie Dusserre, Ph.D. - Vice President of Manufacturing and Regulatory Affairs of Cytograft Tissue Engineering

Dr. Dusserre received her Ph.D. in Cell Biology and Microbiology from Claude Bernard University in Lyon, France. She was a post-doctoral fellow at the Infectious Diseases Research Center at Laval University in Quebec Canada and a postgraduate researcher in the Department of Bioengineering at the University of California, San Diego.

As the Vice President of Manufacturing and Regulatory Affairs at Cytograft Tissue Engineering, Dr. Dusserre oversees all regulatory aspects of Cytograft's operations. Under her leadership, Cytograft has successfully acquired commercial licensure in Germany and clinical licensure in Poland, Slovakia and the United Kingdom. She is also currently leading interactions with the FDA regarding the recent submission of an IND application for LifeLine™. In addition to her regulatory role, Dr. Dusserre also manages Cytograft's manufacturing and research teams.